Core Viewpoint - SelectQuote, Inc. is facing a securities fraud class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misrepresentations about its business practices [4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased SelectQuote securities between September 9, 2020, and May 1, 2025 [4]. - The allegations include that the Company and certain senior officers made misrepresentations regarding the legality of its business practices [4]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiff must file papers by October 10, 2025, with the role involving acting on behalf of other class members [5]. - Participation as a lead plaintiff is not required to share in any potential recovery, and shareholders incur no fees or expenses as representation is on a contingency fee basis [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [6]. - The firm has been recognized multiple times in The National Law Journal's "Plaintiffs' Hot List" and has been listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, of the upcoming lead plaintiff deadline on October 10, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased SelectQuote securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements, including directing Medicare beneficiaries to plans that compensated SelectQuote rather than providing unbiased comparisons [4]. - It is claimed that SelectQuote received illegal kickbacks to steer Medicare beneficiaries to certain insurers, which resulted in non-compliance with applicable laws and regulations [4]. - The lawsuit asserts that the misleading statements about SelectQuote's business operations led to investor damages when the true details became public [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and illegal kickbacks related to Medicare beneficiaries [4][6][7]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of the quality of the plans [6]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [6]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to at least 2021 [7]. Group 2: Impact on Stock and Legal Proceedings - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually heavy trading volume [7]. - Investors who purchased SelectQuote securities between September 9, 2020, and May 1, 2025, are encouraged to discuss their legal rights and options [4][9]. - There is a deadline of October 10, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against SelectQuote [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action by October 10, 2025 [1][3][4]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of the quality of the plans [3]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [3][4]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021, leading to a significant drop in stock price by 19.2% to $2.56 per share on May 1, 2025 [4]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses in SelectQuote are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][6]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the ability to share in any recovery not affected by the decision to serve as lead plaintiff [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, of the upcoming lead plaintiff deadline on October 10, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought SelectQuote securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The lead plaintiff will represent other class members in directing the litigation [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its number of settlements since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements and failed to disclose critical information regarding its business practices [4]. - Specific allegations include directing Medicare beneficiaries to insurers that compensated SelectQuote, not providing unbiased comparisons, receiving illegal kickbacks, and non-compliance with laws and regulations [4]. - The lawsuit claims that these actions led to misleading positive statements about SelectQuote's business, resulting in investor damages when the truth was revealed [4].

Core Viewpoint - SelectQuote Inc. is under legal scrutiny due to a whistleblower lawsuit alleging deceptive sales practices, leading to a significant drop in its stock price and a class-action lawsuit from investors [1][4][5] Legal Issues - The U.S. Department of Justice intervened in a lawsuit claiming SelectQuote misled investors about its business model and regulatory risks, particularly regarding its Medicare Advantage sales practices [1][2][3] - The lawsuit alleges that SelectQuote received tens of millions of dollars in improper payments and directed customers away from lower-margin plans, violating federal statutes including the False Claims Act [3][7] Market Impact - Following the DOJ's involvement, SelectQuote's stock price fell nearly 20% on May 1, 2025, and has since declined over 40% in the past six months, reflecting investor concerns about legal exposure and reputational damage [4][5] Class-Action Lawsuit - The class-action lawsuit, Pahlkotter v. SelectQuote Inc., covers investors who purchased stock between September 9, 2020, and May 1, 2025, alleging that the company failed to disclose material risks related to its sales practices [2][5] - Hagens Berman, the law firm representing the investors, is investigating potential revenue manipulation and deceptive conduct by SelectQuote [6]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of violations of federal securities laws related to misleading statements and illegal kickbacks [4][6][7] Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of quality [6] - SelectQuote is accused of failing to provide unbiased comparisons for Medicare Advantage insurance plans [6] - The company allegedly received illegal kickbacks from health insurers to steer beneficiaries towards certain plans, limiting enrollment in competitors' offerings [6] - SelectQuote's actions reportedly made it vulnerable to regulatory and legal sanctions, including violations of the False Claims Act [6] - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021 [7] Group 2: Impact on Stock and Legal Proceedings - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually high trading volume [7] - Investors who suffered losses are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [4][9] - There is an October 10, 2025 deadline for investors to seek the role of lead plaintiff in the federal securities class action against SelectQuote [4]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, due to allegations of misconduct related to Medicare Advantage plans [1][2]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company the most, regardless of the quality of those plans [2]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [2][3]. - The U.S. Department of Justice filed a complaint against SelectQuote, stating that the company received "tens of millions of dollars" in illegal kickbacks from 2016 to at least 2021 [3]. Group 2: Impact on Stock and Legal Proceedings - Following the DOJ's allegations, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025 [3]. - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 10, 2025 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, of the upcoming lead plaintiff deadline on October 10, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought SelectQuote securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2] - The lead plaintiff must file a motion with the Court by October 10, 2025, to represent other class members [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements and failed to disclose critical information regarding its business practices, including directing Medicare beneficiaries to insurers that compensated SelectQuote the most [4] - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage plans and received illegal kickbacks, leading to potential regulatory and legal sanctions [4] - The misleading statements from SelectQuote resulted in investor damages when the true nature of the company's practices became known [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and illegal kickbacks related to Medicare beneficiaries [4][6][7]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of the quality of the plans [6]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [6]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021 [7]. Group 2: Financial Impact - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually heavy trading volume [7]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $75,000 between September 9, 2020, and May 1, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1][4]. - There is an October 10, 2025, deadline for investors to seek the role of lead plaintiff in the federal securities class action against SelectQuote [4][8].